# LungScreenAI - Venture Specification

**Date:** 2026-03-02
**Category:** Healthcare AI / Medical Imaging
**Status:** GO - Pursue
**Agent Score:** 8.50/10

---

## Executive Summary

LungScreenAI is an AI-powered platform for radiologists that automates lung cancer screening LDCT (Low-Dose CT) interpretation, pulmonary nodule detection, malignancy scoring (Lung-RADS), nodule growth tracking, and automated reporting. The platform serves as an AI assistant for lung cancer screening programs, helping radiologists detect early-stage lung cancer when it is curative.

**The Opportunity:** Lung cancer is the #1 cancer killer in the US (120,000+ deaths annually), yet early detection through LDCT screening achieves 80%+ cure rates. The USPSTF expanded screening eligibility in 2021 to 15M Americans, creating a rapidly growing screening market.

**The Solution:** 3D CNN-based computer vision that detects pulmonary nodules as small as 5mm, measures nodule size (volumetric analysis), assigns Lung-RADS scores, tracks nodule growth over time (time-series comparison), and generates standardized screening reports.

**Key Metrics:**
- Target Market: 35,000+ radiologists in the US
- Revenue Potential: $450K MRR by Year 3
- Price Point: $2,000-$5,000/month per hospital
- CAC: $400 | LTV: $90,000 | Gross Margin: 85%

---

## Name

**LungScreenAI - Lung Cancer Screening & Nodule Detection Platform**

---

## Core Concept

AI-powered platform for radiologists that automates:
- **3D LDCT nodule detection** - Detect pulmonary nodules >=5mm using 3D CNN
- **Volumetric nodule sizing** - Precise 3D measurements (more accurate than 2D diameter)
- **Lung-RADS classification** - Automated malignancy scoring (1-4X categories)
- **Time-series growth tracking** - Compare current vs. prior scans for nodule growth
- **Priority scoring** - Flag suspicious nodules for radiologist review first
- **Automated screening reports** - Lung-RADS compliant reports with measurements
- **Nodule registry** - Longitudinal tracking of all detected nodules

**Value Proposition:** "Detect 5mm nodules that radiologists miss, enabling curative resection for early-stage lung cancer."

---

## Problem Statement

### Market Pain Points

| Problem | Impact | Stakeholder | Severity |
|---------|--------|-------------|----------|
| **#1 cancer killer** | 120,000+ deaths annually in US | Patients, Public Health | Catastrophic |
| **Late-stage diagnosis** | 5-year survival <5% when advanced | Patients | Catastrophic |
| **Early detection = curable** | 80%+ cure when detected early | Patients, Radiologists | High |
| **Nodules easy to miss** | 200-500 images per LDCT scan | Radiologists | High |
| **5mm nodules = invisible** | Human visual acuity limit | Radiologists | Critical |
| **Growth tracking manual** | Time-intensive comparison | Radiologists, Screening Programs | Moderate |
| **Lung-RADS reporting** | Standardization compliance burden | Radiologists | Low-Medium |

### By The Numbers

**Mortality Impact:**
- **120,000+** lung cancer deaths annually in the US (more than breast, prostate, colon combined)
- **#1 cancer killer** for both men and women
- **5-year survival:** <5% (late stage) vs. 80%+ (early stage)
- **21M+** Americans at high risk (smokers, aged 50-80)

**Screening Growth:**
- **15M Americans** now eligible for screening (USPSTF 2021 expansion)
- **10M+ LDCT screenings** performed annually (growing 25% YoY)
- **2,500+** lung cancer screening programs in the US (rapidly growing)

**Radiology Reality:**
- **35,000+** radiologists in the United States
- **200-500 images** per LDCT scan (time-consuming to review)
- **5mm nodules** = visual threshold (easy to miss, potentially deadly)
- **30+ minutes** per screening scan (without AI assistance)

**Clinical Need:**
- **Small nodule detection** = curative lung cancer resection
- **Missed 5mm nodule** = late-stage diagnosis within 1-2 years
- **Volume doubling time** = key malignancy indicator (requires AI tracking)
- **Lung-RADS adoption** = standardization requirement for screening programs

### The "FIFO" Problem in Screening

Most lung cancer screening programs process LDCTs in first-in, first-out order. A scan with a suspicious 8mm nodule processed identically to a negative scan delays potential curative intervention. AI prioritization moves suspicious scans to the front of the queue.

---

## Target Vertical

### Primary Customer: Radiologists in Lung Cancer Screening Programs

**Thoracic Radiologists**
- High-volume lung cancer screening programs
- Academic medical centers
- Comprehensive cancer centers
- Specialized thoracic imaging practices

**General Radiologists (LDCT Interpretation)**
- Community hospital radiology groups
- Outpatient imaging centers
- Teleradiology firms (nighthawk/weekend coverage)
- Rural hospital radiologists

**Lung Cancer Screening Program Directors**
- Hospital-based screening programs
- Freestanding screening centers
- Health system screening networks
- VA medical centers

### Secondary Customers

**Hospital Administrators**
- Quality metrics (early detection rates)
- Cancer center accreditation (Commission on Cancer)
- Population health initiatives
- Malpractice risk reduction

**Oncology Departments**
- Earlier referrals for suspicious nodules
- Surgical planning support (nodule localization)
- Multidisciplinary tumor board support

**Pulmonary Medicine**
- Nodule follow-up tracking
- Biopsy planning assistance
- Shared care coordination

### Buyer Personas

**1. Dr. Sarah Mitchell - Thoracic Radiologist**
- Academic medical center
- 50+ LDCT screenings per week
- Pain: Fear of missing small nodules, time pressure
- Budget: Department-level decision

**2. Dr. James Rodriguez - Screening Program Director**
- Community hospital screening program
- 200+ screenings monthly, growing rapidly
- Pain: Reporting burden, quality metrics, accreditation
- Budget: Hospital procurement

**3. Dr. Emily Chen - General Radiologist**
- Teleradiology firm (nighthawk reads)
- Mix of ED, inpatient, and screening reads
- Pain: Fatigue, lack of thoracic specialization
- Budget: Practice group decision

---

## Why Now

### Market Timing Factors

| Factor | Trend | Impact |
|--------|-------|--------|
| **USPSTF Expansion (2021)** | Eligibility expanded 50-80yo, 20 pack-years | 15M Americans eligible |
| **Screening Program Growth** | 2,500+ programs (25% YoY growth) | Rapid market expansion |
| **Lung-RADS Standardization** | ACR-mandated reporting | Compliance need |
| **3D CNN Maturation** | Proven for CT nodule detection | Technology ready |
| **GPU Cloud Access** | HIPAA-compliant GPU infrastructure | Deployment feasible |
| **Mortality Urgency** | #1 cancer killer = highest priority | Clinical imperative |
| **COVID Lung Scarring** | Post-COVID nodule differentiation | New use case |

### Technology Readiness

1. **3D CNNs** proven for LDCT nodule detection (Nature Medicine 2019-2025)
2. **Volumetric analysis** superior to 2D diameter measurements
3. **Time-series comparison** algorithms mature (registration, growth tracking)
4. **MONAI framework** optimized for medical imaging 3D CNNs
5. **GPU infrastructure** accessible via cloud (AWS HIPAA regions)
6. **FDA pathways** clearer for AI/ML SaMD (Software as Medical Device)

### Clinical Validation Landscape

- **NLST (National Lung Screening Trial)** proved LDCT mortality benefit
- **NELSON trial** confirmed volumetric nodule measurement superiority
- **Lung-RADS** standardized reporting (ACR 2019, updated 2022)
- **Multiple AI nodule detection studies** published (Radiology, AJR)

---

## AI Advantage

### Why AI Is The Right Solution

LDCT scans are **ideal for AI:**
1. **3D structured data** (200-500 contiguous slices)
2. **High contrast** (lung parenchyma = dark, nodules = bright)
3. **Standardized protocols** (low-dose, consistent acquisition)
4. **Quantitative** (nodule size, density, volume doubling time)
5. **Time-series comparison** (prior scan registration = AI strength)

### Technical Approach

**3D Convolutional Neural Networks (CNNs)**
- Process LDCT volumes as 3D tensors
- Detect spherical/irregular nodules across contiguous slices
- Learn nodule characteristics (spiculation, density, margins)

**Key Architectures:**
- **3D U-Net** for nodule segmentation
- **3D ResNet/DenseNet** for nodule classification
- **Vision Transformers (ViT)** for 3D medical imaging
- **Siamese networks** for time-series comparison

**MONAI Framework**
- Medical imaging optimized
- DICOM native support
- 3D data pipelines
- Pre-trained models for transfer learning

### AI Capabilities

| Capability | AI Method | Clinical Value |
|------------|-----------|----------------|
| **Nodule Detection** | 3D CNN object detection | Catch 5mm nodules humans miss |
| **Volumetric Sizing** | 3D segmentation | More accurate than 2D diameter |
| **Lung-RADS Scoring** | Multi-feature classification | Standardized malignancy risk |
| **Growth Tracking** | Siamese networks + registration | Volume doubling time = malignancy |
| **Nodule Characterization** | Density/texture analysis | Solid vs. ground-glass distinction |
| **Priority Scoring** | Ensemble malignancy model | Queue triage (suspicious first) |
| **Report Generation** | Template-based + LLM | Lung-RADS compliant reports |

### The Moat: Time-Series Growth Tracking

**Nodule growth = strongest malignancy predictor:**
- Volume doubling time <400 days = highly suspicious
- Stable nodule over 2+ years = likely benign
- **AI excels at:** Precise 3D volumetric comparison over time
- **Manual limitation:** Human estimation error, time-consuming
- **Competitor gap:** Most AI tools lack longitudinal tracking

---

## Viral Mechanism

### Organic Growth Channels

**Professional Conferences**
- **IASLC** (International Association for Study of Lung Cancer) - World Conference on Lung Cancer
- **RSNA** (Radiological Society of North America) - Thoracic Imaging track
- **ACR** (American College of Radiology) - Lung Cancer Screening Committee
- **STR** (Society of Thoracic Radiology) - Annual meeting

**Case Study Virality (Highest Potential)**
- "This AI detected a 5mm nodule I missed" = VIRAL
- **Curative resection stories:** "Patient cured because AI caught early cancer"
- **Anonymous case sharing:** Diagnostic challenge series
- **Before/after comparisons:** AI-assisted vs. unassisted detection

**Referral Network**
- **Lung cancer screening program directors** share best practices
- **ACR Lung Cancer Screening Registry** participants network
- **NCCN member institutions** (National Comprehensive Cancer Network)
- **Teleradiology firm adoption** (vRad, RadNet)

### The "Curative Detection" Narrative

**Why this goes viral:**
- **Life-saving impact** = dramatic, emotional stories
- **Radiologist relief** = "AI saved me from missing cancer"
- **Patient testimonials** = "Early detection saved my life"
- **Hospital press releases** = "First in region to adopt life-saving AI"

**Example Case Study:**
> "A 62-year-old smoker underwent routine LDCT screening. The AI flagged a 6mm spiculated nodule in the right upper lobe that the radiologist initially overlooked. PET-CT confirmed hypermetabolic activity. Biopsy revealed adenocarcinoma. Surgical resection achieved clear margins. Patient is now 3 years cancer-free."

This type of story spreads rapidly at conferences, on social media, and through hospital networks.

---

## Revenue Model

### Pricing Tiers

| Tier | Price | Features | Target |
|------|-------|----------|--------|
| **Starter** | $2,000/month | Nodule detection + volumetric sizing | Small hospitals, startup screening programs |
| **Professional** | $2,500/month | Full suite + Lung-RADS + growth tracking | Medium hospitals, established programs |
| **Enterprise** | $5,000/month | Multi-hospital + research + API + white-label | Health systems, academic centers |

### Additional Revenue Streams

**Per-Scan Add-on**
- $5 per AI-analyzed LDCT beyond included tiers
- Volume discounts for high-volume programs
- Custom pricing for enterprise contracts

**Implementation Fees**
- One-time $5,000 for PACS/EHR integration
- Custom workflow configuration
- On-site training: $2,000/day

**Training & Support**
- Annual support contract: 20% of license
- Quarterly model updates included
- CME accreditation for radiologist training

### Unit Economics

| Metric | Value | Notes |
|--------|-------|-------|
| **CAC** | $400 | IASLC, RSNA conference booths, webinars |
| **ARPU** | $2,500/month | Weighted average across tiers |
| **Retention** | 36 months | High switching costs (workflow, data) |
| **LTV** | $90,000 | ARPU × 36 months |
| **Gross Margin** | 85% | Cloud compute, FDA compliance costs |
| **LTV:CAC** | 225:1 | Excellent |
| **Sales Cycle** | 6-12 months | Hospital procurement timeline |
| **Churn** | <5% annually | High switching costs, workflow integration |

### Revenue Projections

#### Year 1: Market Entry
- **Target:** 12 hospitals/screening programs
- **MRR:** $30,000
- **ARR:** $360,000

#### Year 2: Expansion
- **Target:** 60 programs + enterprise accounts
- **MRR:** $150,000
- **ARR:** $1,800,000

#### Year 3: Scale
- **Target:** 180 programs + multi-hospital systems
- **MRR:** $450,000
- **ARR:** $5,400,000

### Market Size (TAM/SAM/SOM)

| Segment | Definition | Size |
|---------|------------|------|
| **TAM** | Global lung cancer screening AI market | $4.2B by 2030 |
| **SAM** | US lung cancer screening programs | $800M annually (2,500+ programs) |
| **SOM** | Early adopter programs (10% penetration) | $80M annually |

---

## MVP Roadmap (8 Weeks)

### Weeks 1-2: Data Collection & Setup
**Objectives:**
- Secure lung cancer screening program partnership
- Establish LDCT data pipeline
- Set up infrastructure

**Deliverables:**
- IRB/Data use agreement with one screening program
- 500+ annotated LDCT studies (with nodule labels)
- DICOM to training format pipeline
- AWS HIPAA-compliant infrastructure
- FastAPI backend scaffold
- MONAI/PyTorch environment

### Weeks 3-5: 3D Nodule Detection Model
**Objectives:**
- Build 3D CNN for nodule detection
- Target >95% sensitivity for 5mm+ nodules
- Validate on held-out test set

**Deliverables:**
- 3D CNN model (3D U-Net or similar)
- Training pipeline with data augmentation
- Nodule detection benchmark (>95% sensitivity, >85% specificity)
- Model interpretability (visualizations)

### Weeks 6-7: Pilot Integration
**Objectives:**
- Integrate with one screening program PACS
- Deploy model in pilot environment
- Collect validation metrics

**Deliverables:**
- Live pilot with one lung cancer screening program
- AI vs. radiologist comparison study
- Time-to-detection metrics
- UI prototype for nodule viewer

### Week 8: Refinement & Demo Prep
**Objectives:**
- Refine model based on pilot feedback
- Prepare conference demo

**Deliverables:**
- Model refinement (iteration based on pilot)
- IASLC/RSNA demo deck
- Case study materials
- Pilot testimonial (if successful)
- Go/No-Go decision metrics

### MVP Validation Metrics

| Metric | Target | Why |
|--------|--------|-----|
| **Sensitivity** | >0.95 | Cannot miss 5mm+ nodules (curative window) |
| **Specificity** | >0.85 | Avoid excessive false positives |
| **Nodule detection rate** | 20%+ higher than unassisted | Measurable clinical impact |
| **Pilot commitment** | 1+ program commits post-pilot | Commercial validation |
| **AUC-ROC** | >0.90 | Model quality |

---

## Tech Stack

### Backend & Infrastructure

| Component | Technology | Rationale |
|-----------|------------|-----------|
| **Backend** | Python/FastAPI | Async, fast development, medical imaging ecosystem |
| **AI Framework** | PyTorch + MONAI | Medical imaging optimized, 3D CNN support |
| **DICOM Processing** | pydicom, GDCM, HighDICOM | Industry standard for medical imaging |
| **Task Queue** | Celery + Redis | Async scan processing |
| **Database** | PostgreSQL | Patient data, nodules, Lung-RADS scores |
| **Storage** | AWS S3 (HIPAA) | LDCT volume storage (100-300MB per scan) |
| **GPU Compute** | AWS p3/p4 instances | Model training and inference |

### Integrations

**PACS (Picture Archiving and Communication System)**
- DICOM listeners for incoming LDCT studies
- HL7 messages for study orders/results
- Modality worklist integration

**EHR (Electronic Health Records)**
- Epic (Interconnect, FHIR)
- Cerner (Millennium platform)
- Meditech

**RIS (Radiology Information Systems)**
- Study status updates
- Report generation
- Lung-RADS registry integration

### Compliance & Security

- **HIPAA compliant** infrastructure (AWS BAA)
- **SOC 2 Type II** certification (planned Year 1)
- **FDA Class II** pathway (510(k) de novo or predicate)
- **Audit logging** for all patient data access
- **Encryption at rest and in transit**

### Frontend

- **Framework:** React + TypeScript
- **CT Viewer:** Cornerstone.js (DICOM web viewer)
- **UI Components:** Tailwind CSS + shadcn/ui
- **Nodule overlay:** Canvas/WebGL annotations

---

## Risk Factors

### Regulatory Risks

| Risk | Impact | Timeline | Mitigation |
|------|--------|----------|------------|
| **FDA Class II pathway** | Required for commercial use | 12-24 months, $1-2M | Start with research-only, engage FDA counsel early |
| **Reimbursement unclear** | Hospital budget resistance | Ongoing | ROI on early detection metrics, malpractice reduction |
| **State medical board rules** | Varying AI practice rules | Varies | Position as "decision support," radiologist stays decision-maker |

### Technical Risks

| Risk | Impact | Mitigation |
|------|--------|------------|
| **LDCT data quality variability** | Model performance degrades | Data augmentation, domain adaptation, multi-scanner training |
| **False negatives** | Missed cancer = patient harm | >0.95 sensitivity target, conservative thresholds, radiologist review |
| **False positives** | Alarm fatigue, unnecessary follow-up | >0.85 specificity target, learning from feedback |
| **Small nodule detection** | <5mm nodules extremely challenging | Focus on 5mm+ initially (clinical consensus threshold) |
| **PACS integration complexity** | Long deployment cycles | Pre-built integrations for major vendors (GE, Philips, Siemens) |

### Commercial Risks

| Risk | Impact | Mitigation |
|------|--------|------------|
| **Screening program sales cycles** | 6-12 month sales cycles | Target radiology groups (shorter cycles) |
| **Competition** | Riverain, MaxQ AI, others exist | Focus on screening + Lung-RADS + time-series differentiation |
| **Radiologist resistance** | "AI will replace me" fears | Augmentation narrative, radiologist advisors, transparent AI |
| **Hospital IT barriers** | Security concerns, deployment hesitancy | Cloud deployment, SOC 2, HIPAA compliance, reference customers |

### Clinical Risks

| Risk | Impact | Mitigation |
|------|--------|------------|
| **Model drift** | Performance degrades over time | Continuous monitoring, retraining pipeline, feedback loop |
| **New CT protocols** | Model fails on new scanners | Ongoing data collection, domain adaptation, scanner partnerships |
| **Liability** | Misdiagnosis lawsuits | Clear product labeling, radiologist stays decision-maker, malpractice insurance |
| **Over-diagnosis** | Detecting indolent cancers | Lung-RADS conservative follow-up guidelines |

---

## Competitive Analysis

### Direct Competitors

| Company | Focus | Strength | Weakness vs. LungScreenAI |
|---------|-------|----------|---------------------------|
| **Riverain Technologies** | Nodule detection (ClearRead) | FDA cleared, established | General radiology, not screening-specific |
| **MaxQ AI** | Lung nodule AI | Triage focus | Not Lung-RADS focused |
| **GE Healthcare** | CT AI features | Installed base (CT scanners) | Hardware-locked, not workflow-focused |
| **Siemens Healthineers** | AI-RAD Companion | Scanner integration | Hardware vendor, not software-first |
| **4D Lung** | Lung nodule analysis | 4D imaging focus | Limited adoption, not screening-focused |
| **Imbio** | Lung analysis (COPD) | Quantitative lung metrics | COPD focus, not cancer screening |

### General Radiology AI Platforms

| Company | Focus | Weakness vs. LungScreenAI |
|---------|-------|---------------------------|
| **Aidoc** | General radiology triage | Not screening/Lung-RADS specific |
| **Annalise.ai** | Comprehensive radiology AI | Expensive, not US screening-focused |
| **RadNet AI** | Teleradiology-owned | Limited to RadNet network |

### Hospital In-House AI

- **Academic centers** building custom nodule detection models
- **Advantage:** Domain expertise, data access
- **Disadvantage:** Slow development, lack of commercialization, poor UI

### Differentiation Strategy

**Only platform focused on LUNG CANCER SCREENING:**
- **3D nodule detection + Lung-RADS + time-series growth tracking** = integrated suite
- **Lung-RADS native** (not generic radiology AI)
- **Time-series comparison** (growth tracking = moat)
- **Screening workflow** (not general radiology)
- **Curative detection narrative** (life-saving impact)

---

## Go/No-Go Decision: GO

**Score: 8.50/10 - PURSUE**

### Critical Success Factors

#### 1. Hire Thoracic Radiologists as Co-Founders/Advisors
- Clinical credibility with customer base
- Lung-RADS workflow understanding
- FDA pathway navigation
- Access to screening program networks
- Data acquisition partnerships

#### 2. Partner with One Lung Cancer Screening Program
- Real-world feedback loop
- Pilot site for validation
- Reference customer for sales
- Data access for model training
- CME accreditation opportunities

#### 3. Start with Nodule Detection (Clear ROI)
- Highest clinical urgency (early detection = curative)
- Binary detection (nodule present/absent = AI-friendly)
- Measurable impact (detection rate improvement)
- Clear workflow integration (prioritize suspicious scans)

#### 4. Focus on Growth Tracking (The Moat)
- Time-series comparison = AI strength
- Volume doubling time = strongest malignancy predictor
- Competitors lack longitudinal tracking
- High switching costs (historical data)
- Differentiation from generic nodule detection

#### 5. Build IASLC/RSNA Conference Relationships
- IASLC World Conference on Lung Cancer (primary)
- RSNA Thoracic Imaging Track (secondary)
- ACR Lung Cancer Screening Committee
- STR (Society of Thoracic Radiology)
- Thought leadership platform

### Decision Rationale

**PURSUE** for founders with:
- Medical AI/computer vision expertise
- Thoracic radiologist co-founder access
- 18-24 month runway (includes FDA pathway)
- High risk tolerance
- Mission-driven (saving lives)

**NOT SUITABLE** for:
- First-time founders without medical AI experience
- Solo founders
- Short runway (<12 months)
- Risk-averse profiles

### Why This Scores 8.50

**Strengths:**
- **#1 cancer killer** (120,000 deaths) = highest mortality urgency
- **3D LDCT nodule detection** = perfect AI-native application
- **USPSTF expansion** = 15M Americans newly eligible
- **Early detection = curative** (80%+ survival) = strong clinical case
- **Time-series growth tracking** = competitive moat
- **High switching costs** (longitudinal data) = low churn
- **LTV:CAC 225:1** = excellent unit economics
- **Curative detection stories** = viral marketing potential

**Weaknesses:**
- **FDA Class II pathway** required (12-24 months, $1-2M)
- **Competition exists** (Riverain, MaxQ AI, others)
- **Cannot miss nodules** (>0.95 sensitivity bar = high)
- **Screening program sales cycles** = 6-12 months
- **Technical complexity** (3D CNN, time-series registration)

**The Verdict:**
This is a **life-saving AI application** with the highest mortality urgency (#1 cancer killer) and clear AI-native technical fit. The combination of curative detection potential, growing screening market (USPSTF expansion), and time-series growth tracking moat makes this worth pursuing.

The key is **focus**: Lung cancer screening only (not general radiology), 5mm+ nodule detection threshold (clinical consensus), and growth tracking as the differentiating moat.

---

## Implementation Checklist

### Pre-Launch
- [ ] Recruit thoracic radiologist co-founder/advisor
- [ ] Form clinical advisory board
- [ ] Secure lung cancer screening program partnership
- [ ] Obtain IRB approval
- [ ] Set up HIPAA-compliant infrastructure
- [ ] Engage FDA regulatory consultant

### MVP Development
- [ ] Collect 500+ annotated LDCT studies
- [ ] Build 3D nodule detection CNN
- [ ] Validate >0.95 sensitivity for 5mm+ nodules
- [ ] Deploy pilot with screening program
- [ ] Create LDCT viewer with nodule overlays
- [ ] Prepare IASLC/RSNA demo

### Post-MVP
- [ ] Implement volumetric nodule sizing
- [ ] Build Lung-RADS classification
- [ ] Develop time-series growth tracking
- [ ] Initiate FDA 510(k) or de novo submission
- [ ] Publish validation study in Radiology/AJR
- [ ] Scale to 10+ screening programs
- [ ] Raise Series A for regulatory + commercialization

---

## Next Steps

### Immediate Actions (Week 1)

1. **Form founding team**
   - Technical co-founder (ML/medical imaging)
   - Clinical co-founder/advisor (thoracic radiologist)
   - Regulatory advisor (FDA pathways)

2. **Secure pilot partnership**
   - Identify lung cancer screening program for pilot
   - Draft MOU for data access/validation

3. **Begin data collection**
   - IRB application for LDCT dataset access
   - Identify public datasets (NLST, LUNA16, LIDC)

4. **Build regulatory roadmap**
   - Engage FDA counsel
   - Map 510(k) pathway with predicate devices

### Milestones for First 6 Months

| Month | Milestone | Success Criteria |
|-------|-----------|------------------|
| 1-2 | Data collection + model setup | 500+ LDCT studies annotated |
| 3-5 | Nodule detection model | >0.95 sensitivity, >0.85 specificity |
| 5-6 | Pilot deployment | 1 screening program live |
| 6 | Pilot results | 20%+ detection rate improvement |
| 6-8 | Fundraising / FDA filing | Seed round or 510(k) submission |

---

## Appendix: Key Resources

### Datasets
- **NLST** (National Lung Screening Trial) - 50,000+ LDCT scans
- **LUNA16** - Lung Nodule Analysis 2016 challenge
- **LIDC-IDRI** - Lung Image Database Consortium
- **Data Science Bowl 2017** - Lung cancer detection Kaggle challenge

### Frameworks
- **MONAI** (Medical Open Network for AI)
- **PyTorch Medical Imaging**
- **NVIDIA Clara** (medical imaging SDK)
- **HighDICOM** (DICOM extensions)

### Regulatory
- **FDA Software as a Medical Device (SaMD)** guidelines
- **510(k) pathway** resources
- **Lung-RADS v1.1** (ACR 2022)
- **DICOM standards**

### Conferences
- **IASLC World Conference on Lung Cancer** (Primary target)
- **RSNA Annual Meeting** - Thoracic Imaging track
- **ACR** - Lung Cancer Screening Committee meetings
- **STR** (Society of Thoracic Radiology) Annual Meeting
- **SIIM** (Society for Imaging Informatics in Medicine)

### Key Publications
- **NLST Research Team** (2011) "Reduced Lung-Cancer Mortality with LDCT Screening" - NEJM
- **NELSON Trial** (2020) "Volume-Doubling Time" - Lancet Oncology
- **ACR Lung-RADS** (2022) v1.1 Assessment Categories
- **Ardila et al.** (2019) "End-to-end lung cancer screening" - Nature Medicine

---

**Venture Spec Version:** 1.0
**Last Updated:** 2026-03-02
**Status:** GO - Proceed to MVP development
**Confidence:** 8.50/10
